Business
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease Six Month Interim Results Expected in 1H 2026 Topline Results Anticipated by end of 2026 CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral s
About this update from Promis Neurosciences Inc.
[{"type":"image","alt":"ProMIS Neurosciences Inc.","displaySize":"","headline":null,"caption":"ProMIS Neurosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UIdpZ5Ja0S7N6QhO5P0RBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125}},"lazy":false},{"type":"text","content":"First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer’s Disease ","length":83,"tagName":"p"},{"type":"text","content":"Six Month Interim Results Expected in 1H 2026 ","length":45,"tagName":"p"},{"type":"text","content":"Topline Results Anticipated by end of 2026","length":42,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Massachusetts, May 12, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD) and multiple system atrophy (MSA), today announced financial results for the first quarter ended March 31, 2025.","length":480,"tagName":"p"},{"type":"text","content":"“We made significant progress in the first quarter of 2025, advancing our lead clinical program in Alzheimer’s disease with rapid enrollment of the first cohort in the PRECISE-AD trial,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “The pace of enrollment exceeded our expectations, reflecting the growing enthusiasm from investigators for PMN310’s differentiated profile. Based on its selective targeting of toxic Aβ oligomers and the potential to avoid ARIA—a serious safety concern seen with existing therapies—we believe PMN310 could set a new standard as a best-in-class treatment for Alzheimer’s treatment. Delivering a therapy that combines strong efficacy with a substantially improved safety profile would be a transformative milestone for patients and caregivers.”","length":795,"tagName":"p"},{"type":"text","content":"“While PRECISE-AD is designed as a 12-month, double-blind study, it is powered to detect biomarker ...